A study by Sobhani et al. [68] reported that a selective use of a CTLA-4 inhibitor demonstrated a significant reduction in tumor growth in a melanoma murine model, while exhibiting a lower incidence of irAEs compared to conventional CTLA-4 blockade therapies. The gene discussed is CTLA4; the disease is neoplasm.